Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $16.14 Average Price Target from Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $16.1429.

IVA has been the topic of several research analyst reports. HC Wainwright boosted their target price on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Wall Street Zen raised Inventiva to a “hold” rating in a research note on Saturday, October 18th. Guggenheim boosted their target price on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Piper Sandler started coverage on Inventiva in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC lifted its stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,558 shares of the company’s stock after buying an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 as of its most recent filing with the Securities & Exchange Commission. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Stock Performance

NASDAQ:IVA opened at $5.35 on Thursday. Inventiva has a 1-year low of $2.11 and a 1-year high of $6.55. The business has a 50 day moving average of $5.37 and a 200 day moving average of $4.05.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.